Moderna

$153.30
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$6.43 (+4.33%) Today
-$1.51 (-0.98%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Moderna and other stocks, options, and ETFs commission-free!

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA. The listed name for MRNA is Moderna, Inc. Common Stock.

CEO
Stéphane Bancel
Employees
830
Headquarters
Cambridge, Massachusetts
Founded
2010
Market Cap
63.54B
Price-Earnings Ratio
Dividend Yield
Average Volume
9.48M
High Today
$159.60
Low Today
$150.88
Open Price
$157.98
Volume
13.45M
52 Week High
$189.26
52 Week Low
$19.31

MRNA News

MarketWatch7h

Moderna Inc. stock outperforms market on strong trading day

Shares of Moderna Inc. MRNA, +4.33% rose 4.33% to $154.81 Friday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ
BenzingaFeb 25

Here's Why Moderna, Plug Power, AMC, GameStop Are Moving

One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why Is It Moving, or WIIM, feature in Benzing
MarketWatchFeb 25

Moderna reports $570 million in revenue for first time driven by sales of COVID-19 vaccine

Shares of Moderna Inc. MRNA, -3.58% gained 2.2% in premarket trading on Thursday after the company reported half a million dollars in sales of its COVID-19 vacc

MRNA Earnings

-$0.69
-$0.46
-$0.23
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
-$0.69 per share
Replay Earnings Call

You May Also Like

MNSO

More MRNA News

ReutersFeb 25

UPDATE 3-Moderna expects $18.4 billion in COVID-19 vaccine sales in 2021

* Forecasts steep jump cost of sales in 2021 * Study of vaccine in children and adolescents to begin soon * Shares up 4% (Adds share movement, details on cost
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure